Lerociclib Emerging Drug Insight and Market Forecast - 2032

“Lerociclib Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Lerociclib for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the Lerociclib for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the Lerociclib for ER+ve HER2-ve Breast Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Lerociclib market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.

Drug Summary

Lerociclib (EQ132) is a novel, oral, potent, and selective small-molecule cyclin-dependent kinase (CDK) 4/6 inhibitor that has been demonstrated in a Phase I clinical trial in patients with metastatic breast cancer to be highly active in combination with estrogen receptor antagonists with an acceptable tolerability profile. Lerociclib is being studied in a Phase II clinical trial to treat HR+/HER2- metastatic breast cancer.

At the San Antonio Breast Cancer Symposium (SABCS) in December 2019, G1 reported preliminary Phase I/II clinical data in HR+/HER2− metastatic breast cancer.

G1 entered into separate, exclusive agreements with EQRx (rights for the US, Europe, Japan, and all markets outside Asia-Pacific) and Genor (rights for Asia-Pacific, excluding Japan) for the development and commercialization of lerociclib in all indications. EQRx and Genor are responsible for all costs related to the development and commercialization of lerociclib in their respective territories.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Lerociclib description, mechanism of action, dosage and administration, research and development activities in ER+ve HER2-ve Breast Cancer.
• Elaborated details on Lerociclib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Lerociclib research and development activity in ER+ve HER2-ve Breast Cancer in detail across the United States.
• The report also covers the patents information with expiry timeline around Lerociclib.
• The report contains forecasted sales of Lerociclib for ER+ve HER2-ve Breast Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ER+ve HER2-ve Breast Cancer.
• The report also features the SWOT analysis with analyst views for Lerociclib in ER+ve HER2-ve Breast Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Lerociclib Analytical Perspective

In-depth Lerociclib Market Assessment

This report provides a detailed market assessment of Lerociclib in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted sales data from 2026 to 2032.

Lerociclib Clinical Assessment

The report provides the clinical trials information of Lerociclib in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for ER+ve HER2-ve Breast Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Lerociclib dominance.
• Other emerging products for ER+ve HER2-ve Breast Cancer are expected to give tough market competition to Lerociclib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Lerociclib in ER+ve HER2-ve Breast Cancer.
• This in-depth analysis of the forecasted sales data from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Lerociclib in ER+ve HER2-ve Breast Cancer.  

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Lerociclib?
• What is the clinical trial status of the study related to Lerociclib in ER+ve HER2-ve Breast Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Lerociclib development?
• What are the key designations that have been granted to Lerociclib for ER+ve HER2-ve Breast Cancer?
• What is the forecasted market scenario of Lerociclib for ER+ve HER2-ve Breast Cancer?
• What are the forecasted sales of Lerociclib in the United States?
• What are the other emerging products available in ER+ve HER2-ve Breast Cancer and how are they giving competition to Lerociclib for ER+ve HER2-ve Breast Cancer?
• Which are the late-stage emerging therapies under development for the treatment of ER+ve HER2-ve Breast Cancer?

This product will be delivered within 2 business days.